FILTER
LATEST INTERVIEWS
Michel Champagne
PRESIDENT & CEO, SIDEX
A look at investment criteria to support early stage exploration companies in Québec.
Naseem Lahri
MANAGING DIRECTOR, LUCARA BOTSWANA
Lahri gives details about the use of new technologies in diamond mining and the impact of blockchain on traceability.
Raul Rodriguez
PRESIDENT AND CEO, RIGEL
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and commercializing novel small molecule drugs for immune and hematologic disorders, cancer and rare diseases.
Elizabeth Jeffords
CHIEF COMMERCIAL & STRATEGY OFFICER, ALKAHEST
Alkahest has a unique technology platform for elucidating changes in the plasma proteome in healthy aging and in age-related diseases.
Ricardo Diogo
DIRECTOR BUSINESS DEVELOPMENT, OILTANKING
A look at the liquids storage market in Latin America and its potential consolidation.
Michael Quirmbach
CHIEF BUSINESS OFFICER, CORDENPHARMA
CordenPharma is a CDMO supporting pharma and biotech companies, with cGMP facilities across Europe & the US.
Brian Frenzel
CEO, TOSK
Tosk is developing a family of small molecule drugs to prevent the toxic side ef-fects of cancer treatments.
Carlos Ventura
PRESIDENT, BELARUSANGOLA HOLDING LDA
An Angolan company built around partnerships with Belarusian players.
Matthias Vorbeck & Alejandro Gabrielli
GENERAL MANAGER & REGIONAL MANAGER, ANASTACIO OVERSEAS
The company continues expanding in Latin America capitalizing the synergies with the distribution business of Química Anastacio.
Alan Seem
PARTNER, JONES DAY
Jones Day is the largest law firm in the United States and one of the ten largest firms globally.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
